Market Review: A High-Altitude Seesaw—Legal Victories Meet Administrative Blockades
On Monday, February 23, 2026, the South Korean stock market opened with explosive optimism but concluded in a cautious "strong start, weak finish" pattern. The KOSPI rose +0.21% to close at 5,820.79, while the KOSDAQ fell -0.43% to 1,149.03. The session was a direct reflection of the legal battle in Washington; while the U.S. Supreme Court’s ruling against the IEEPA tariffs provided an initial boost, the market turned wary as President Trump invoked Article 122 to maintain a 15% tariff floor, maintaining the status quo of the Korea-U.S. trade negotiations.
1. The Tariff Verdict: Supreme Court vs. Article 122
The global trade narrative took a dramatic turn over the weekend, leading to high-altitude volatility in Seoul.
- The Legal Win: The U.S. Supreme Court ruled that the use of the International Emergency Economic Powers Act (IEEPA) for broad tariffs was illegal, briefly lifting the KOSPI above the 5,900 mark.
- The Counter-Move: The Trump administration immediately pivoted to Article 122 (Indirect Tariffs), ensuring that Korean firms remain under the 15% tariff rate negotiated previously.
- Supply Chain Immunity: Crucially, critical exports such as Semiconductors, Pharmaceuticals, and Autos remain unaffected by this specific administrative shuffling, confirming their status as essential components of the U.S. supply chain.
2. Infrastructure & Energy: The Energy Highway Momentum
Domestic energy and power equipment firms continue to ride a structural super-cycle driven by both U.S. and domestic policy.
- Grid Expansion: Positive analysis regarding North American 765kV transformer orders and the domestic "West Coast Energy Highway" project kept the sector in a high-conviction buy zone.
- Nuclear Export: Expectations for the Korea-U.S. nuclear cooperation remained firm, providing a floor for heavy industry.
- Key Tickers: Iljin Electric (103590) (+13.5%), Woori Technology (032820) (+13.1%), and Daehan Cable (001440) (+4.3%).
3. Tech & Growth: MLCC Price Hikes and Biopharma Policy
Capital is rotating into "Next-Gen Growth" axes as the market awaits Nvidia’s upcoming earnings results.
- MLCC Re-rating: Following the HBM boom, the market is now focusing on MLCC (Multi-Layer Ceramic Capacitors). Anticipation of a significant price hike led Samsung Electro-Mechanics (009150) to surge +11.8%.
- Biopharma Support: The sector received a boost from government promises to support Bio as a primary growth engine similar to Semiconductors. Hyundai Bio (048410) hit the upper limit (+30.0%) on clinical trial expectations for prostate cancer.
- Semiconductor Anchors: Samsung Electronics (005930) managed a +0.9% gain, while SK Hynix edged down -0.2% as investors balanced global earnings jitters.
4. Financial Consolidation: Legislative Delays in the National Assembly
The "Value-up" rally faced a temporary hurdle as political friction delayed key legislative reforms.
- Commercial Code Setback: Reports that the ruling party might boycott the plenary session for the 3rd Commercial Code Amendment triggered profit-taking in the brokerage and insurance sectors.
- Key Tickers: Mirae Asset Securities (006800) (-5.1%) and Korea Investment Holdings (071050) (-5.1%) led the retreat in financials.
Institutional Conviction: Top 5 High-Trend Tickers
While foreigners were net sellers of nearly 1.1 trillion KRW on the KOSPI, institutions and retail buyers focused on specific clinical and structural catalysts:
- Hyundai Bio (048410): Hitting the daily upper limit (+30.0%) on its dual-clinical trial launch and government bio-support.
- Samsung Electro-Mechanics (009150): The top large-cap performer (+11.8%) driven by the MLCC price-cycle recovery.
- Iljin Electric (103590): Leading the infrastructure charge with a +13.5% jump on North American grid expansion.
- Boronoy (336510): Surging +20.0% ahead of the major March bio-conferences and clinical data releases.
- LG Electronics (066570): Gaining +6.6% on growing expectations for its data center cooling/air conditioning business.
Investor Strategy: The KOSPI has entered a "High-Altitude Boxing Range" near its previous peak. While the legal invalidation of IEEPA tariffs is a significant long-term victory, Trump’s administrative persistence (Article 122) ensures that volatility will remain high. We recommend a core focus on MLCC and Biopharma as new growth drivers for the first half of 2026. For the "Value-up" sectors (Securities/Insurance), the current dip should be viewed as a tactical accumulation opportunity ahead of the eventual passage of the Commercial Code Amendment. The floor for the HBM Super-cycle remains firm, but expect lateral movement until fresh directional cues emerge.